Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic (NYSE:MDT) is currently navigating a landscape marked by both promising innovations and significant challenges.

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

We recently compiled a list of the 30 Most Important AI Stocks According to BlackRock. In this article, we are going to take ...

We recently compiled a list titled Jim Cramer’s Latest Watchlist: 10 Stock Picks You Need to Know. In this article, we will ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Medtronic (MDT – Research Report), with a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

He notes that Medtronic plc (NYSE:MDT), which produces devices for cardiovascular, neurological, surgical, and diabetes management, has shown impressive performance. “After the stock hit a 52 ...

Medtronic Diabetes uses machine learning for automatic insulin delivery in the MiniMed 780G System, which features a Meal Detection Technology algorithm. Medtronic plc (NYSE:MDT) has invited ...

Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...

Pharmac – Te Pātaka Whaioranga has decided to fund continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables for people with type 1 diabetes from 1 October 2024.